Table 2. Variations in phenotypic and functional NK-cell parameters as detected in the circulation of multiple myeloma patients.
Ref. | NK cell number | Activation status | Activating receptors | Cytotoxicity | Notes |
---|---|---|---|---|---|
44 |
Increased |
|
|
Unchanged |
Increased NK also in MGUS |
45 |
Unchanged |
Unchanged |
|
|
|
46 |
Increased |
|
|
Decreased |
Increased NK also in MGUS |
47 |
Increased in BM |
|
|
|
Increased NK also in MGUS |
48 |
|
|
Decreased CD16 Decreased CD244 Unchanged KLRK1 Unchanged NCR |
|
Trend toward reduced KLRK1 levels in MM |
49 |
|
|
Decreased KLRK1 |
|
Bortezomib increased MICA levels on MM cells |
50 |
|
|
|
Decreased |
Stage-dependent decrease |
51 |
|
|
Decreased KLRK1 |
|
Not linked with soluble MICA levels |
52 | Increased also in BM |
Abbreviations: BM, bone marrow; KLRK1, killer cell lectin-like receptor subfamily K, member 1; MICA, HC class I polypeptide-related sequence A; MGUS, monoclonal gammopathy of undetermined significance; MM; multiple myeloma; NCR, natural cytotoxicity triggering receptor; NK, natural killer.